According to the latest market intelligence report published by Future Market Insights (FMI), the global biologics market is projected to grow from USD 450.2 billion in 2025 to USD 1,077.2 billion by 2035, registering a compound annual growth rate (CAGR) of 9.1% between 2025 and 2035. Rising demand for targeted therapies, increasing chronic disease prevalence, advances in biotechnology, and expanding applications in oncology and immunology are supporting the market's growth.

Biologics are medicines derived from living organisms or biological systems. They include monoclonal antibodies, recombinant proteins, vaccines, cellular therapies, and gene-based biologics. Their ability to target specific biological pathways has expanded treatment options for cancer, autoimmune disorders, infectious diseases, and rare conditions.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1249

FMI identifies monoclonal antibodies as the leading drug-class segment, accounting for 65.1% of market demand in 2025. Oncology is projected to represent 32.4% of application demand, while hospital pharmacies account for 48.2% of market revenue, reflecting the specialized handling, storage, and administration often required for biologic medicines.

Market Size and Growth Forecasts

·         2025 Baseline Market Value: USD 450.2 billion

·         2035 Projected Market Value: USD 1,077.2 billion

·         Forecast CAGR: 9.1% (2025–2035)

·         Incremental Growth Opportunity: USD 627.0 billion, calculated from the published market values

·         Leading Drug Class: Monoclonal antibodies, with a 65.1% share in 2025

·         Leading Application: Oncology, with a 32.4% share in 2025

·         Leading Distribution Channel: Hospital pharmacies, with a 48.2% share

The projected expansion reflects continued investment in biologic drug development, manufacturing infrastructure, and therapies designed to address unmet medical needs. As the treatment landscape evolves, pharmaceutical companies are focusing on pipeline innovation, production reliability, and broader patient access.

Key Market Segments

By Drug Class

Monoclonal antibodies dominate the biologics market due to their established role in oncology, autoimmune disease treatment, and other therapeutic areas. Advances in antibody engineering, including bispecific antibodies and antibody-drug conjugates, are expanding the range of potential applications.

Recombinant proteins and hormones, vaccines, cellular biologics, gene-based biologics, and therapeutic enzymes also contribute to the market. These categories support a broad range of treatment approaches, from immune protection to targeted interventions for rare and inherited conditions.

By Application

Oncology is projected to account for 32.4% of the market's application demand in 2025. Biologics have become important components of cancer treatment through targeted therapies and immunotherapies. Biomarker-guided treatment selection and continued clinical research are creating opportunities for more individualized therapeutic approaches.

Other applications include autoimmune diseases, infectious diseases, rare diseases, and additional therapeutic areas. The diversity of these applications provides manufacturers with opportunities to develop differentiated portfolios across multiple patient populations.

By Distribution Channel

Hospital pharmacies account for 48.2% of market revenue. Many biologics require specialized storage, controlled distribution, infusion services, or pharmacist oversight, making hospital-based dispensing important for complex therapies.

Retail pharmacies and online pharmacies provide additional distribution channels, depending on the medicine, regulatory requirements, and treatment setting.

Country and Regional Growth Outlook

FMI projects the following country-level CAGRs through 2035:

·         India: 9.5%, supported by expanding healthcare access, pharmaceutical manufacturing capabilities, and demand for advanced therapies.

·         China: 9.0%, driven by investment in biotechnology, cell and gene therapies, and domestic pharmaceutical innovation.

·         South Korea: 8.7%, supported by biotechnology investment and continued development of advanced therapeutic products.

·         France: 4.7%, reflecting demand for innovative medicines and treatment options for an aging population.

·         United Kingdom: 4.1%, supported by biologic therapy adoption and continued pharmaceutical research.

·         Germany: 3.8%, reflecting its established pharmaceutical ecosystem and investment in advanced drug development.

·         United States: 3.7%, supported by biotechnology innovation, regulatory pathways, and demand for specialized therapies.

The report covers North America, Latin America, East Asia, South Asia and Pacific, Western Europe, Eastern Europe, and the Middle East and Africa.

Major Market Trends and Growth Drivers

·         Rising chronic disease burden: Cancer, autoimmune disorders, and other long-term conditions are increasing demand for targeted therapeutic approaches.

·         Next-generation biologics: Bispecific antibodies, antibody-drug conjugates, and fusion proteins are expanding treatment possibilities through differentiated mechanisms of action.

·         Advanced biomanufacturing: Single-use processing systems, modular production facilities, and improved analytical technologies are helping manufacturers develop scalable, quality-controlled production processes.

·         Rare disease incentives: Regulatory incentives, specialized development programs, and increased diagnostic capabilities are encouraging investment in therapies for rare and underserved conditions.

·         Biosimilar development and affordability: Biosimilars can increase treatment options and support cost competition after reference-product exclusivity and other applicable requirements permit market entry. Manufacturing complexity and cold-chain logistics remain important cost considerations.

Access Full Report: https://www.futuremarketinsights.com/reports/biologics-market

Competitive Landscape

The biologics market includes multinational pharmaceutical companies and biotechnology manufacturers competing through research pipelines, product portfolios, manufacturing capacity, and commercialization capabilities. FMI reports that leading companies are investing in innovative therapies, strategic collaborations, and production infrastructure to support demand.

Key companies profiled by FMI include:

·         Amgen, Inc.

·         Eli Lilly and Company

·         GlaxoSmithKline plc

·         AbbVie Inc.

·         F. Hoffmann-La Roche Ltd.

·         Novartis AG

·         Pfizer Inc.

·         AstraZeneca

·         Bayer AG

·         Merck & Co., Inc.

·         Sanofi S.A.

·         Novavax, Inc.

·         Moderna, Inc.

·         Biocon Limited

Competitive differentiation increasingly depends on clinical evidence, regulatory execution, dependable manufacturing, and the ability to bring innovative biologic medicines to patients across multiple markets.

Analyst Perspective

“Biologics market expansion is expected to favor companies able to manage clinical innovation and reliable manufacturing together. Firms with strong antibody portfolios and advanced biologic platforms are likely to gain advantage as hospitals seek proven therapies with steady supply.”

—Anurag Sharma Principal Consultant for Healthcare at Future Market Insights

Related Reports:

·         Aqueous Flare Meter Market - https://www.futuremarketinsights.com/reports/aqueous-flare-meter-market

·         Paraffin Physical Therapy Market - https://www.futuremarketinsights.com/reports/paraffin-physical-therapy-market

·         Multi Dose Drug Vial Adapters Market - https://www.futuremarketinsights.com/reports/multi-dose-drug-vial-adapters-market

About Future Market Insights (FMI)

Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.

For Press & Corporate Inquiries

Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075

For Sales – sales@futuremarketinsights.com
For Media – Rahul.singh@futuremarketinsights.com
For Web – https://www.futuremarketinsights.com